202 related articles for article (PubMed ID: 20105183)
1. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands.
Baker JG; Middleton R; Adams L; May LT; Briddon SJ; Kellam B; Hill SJ
Br J Pharmacol; 2010 Feb; 159(4):772-86. PubMed ID: 20105183
[TBL] [Abstract][Full Text] [Related]
2. Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.
May LT; Briddon SJ; Hill SJ
Mol Pharmacol; 2010 Apr; 77(4):678-86. PubMed ID: 20086038
[TBL] [Abstract][Full Text] [Related]
3. New fluorescent adenosine A1-receptor agonists that allow quantification of ligand-receptor interactions in microdomains of single living cells.
Middleton RJ; Briddon SJ; Cordeaux Y; Yates AS; Dale CL; George MW; Baker JG; Hill SJ; Kellam B
J Med Chem; 2007 Feb; 50(4):782-93. PubMed ID: 17249651
[TBL] [Abstract][Full Text] [Related]
4. A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex.
Alexander SP; Curtis AR; Kendall DA; Hill SJ
Br J Pharmacol; 1994 Dec; 113(4):1501-7. PubMed ID: 7889308
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
Klotz KN; Hessling J; Hegler J; Owman C; Kull B; Fredholm BB; Lohse MJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):1-9. PubMed ID: 9459566
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and direct visualisation of BODIPY-TMR-CGP: a long-acting fluorescent beta2-adrenoceptor agonist.
Baker JG; Hall IP; Hill SJ
Br J Pharmacol; 2003 May; 139(2):232-42. PubMed ID: 12770928
[TBL] [Abstract][Full Text] [Related]
7. Detection of the secondary, low-affinity β1 -adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP.
Gherbi K; Briddon SJ; Hill SJ
Br J Pharmacol; 2014 Dec; 171(23):5431-45. PubMed ID: 25052258
[TBL] [Abstract][Full Text] [Related]
8. Modulation of insulin release by adenosine A1 receptor agonists and antagonists in INS-1 cells: the possible contribution of 86Rb+ efflux and 45Ca2+ uptake.
Töpfer M; Burbiel CE; Müller CE; Knittel J; Verspohl EJ
Cell Biochem Funct; 2008 Dec; 26(8):833-43. PubMed ID: 18979526
[TBL] [Abstract][Full Text] [Related]
9. Role of the second transmembrane domain of rat adenosine A1 receptor in ligand-receptor interaction.
Xie KQ; Cao Y; Zhu XZ
Biochem Pharmacol; 2006 Mar; 71(6):865-71. PubMed ID: 16414025
[TBL] [Abstract][Full Text] [Related]
10. The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor.
Baker JG; Proudman RG; Tate CG
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jul; 384(1):71-91. PubMed ID: 21547538
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in single living cells.
Briddon SJ; Middleton RJ; Cordeaux Y; Flavin FM; Weinstein JA; George MW; Kellam B; Hill SJ
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4673-8. PubMed ID: 15070776
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.
Baker JG; Adams LA; Salchow K; Mistry SN; Middleton RJ; Hill SJ; Kellam B
J Med Chem; 2011 Oct; 54(19):6874-87. PubMed ID: 21870877
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the antagonist affinities for the Gi- and Gs-coupled states of the human adenosine A1-receptor.
Baker JG; Hill SJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):218-28. PubMed ID: 17018691
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
[TBL] [Abstract][Full Text] [Related]
15. Effects of urea pretreatment on the binding properties of adenosine A1 receptors.
May LT; Sexton PM; Christopoulos A
Br J Pharmacol; 2005 Dec; 146(8):1119-29. PubMed ID: 16231004
[TBL] [Abstract][Full Text] [Related]
16. Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity.
Stewart GD; Valant C; Dowell SJ; Mijaljica D; Devenish RJ; Scammells PJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2009 Oct; 331(1):277-86. PubMed ID: 19641164
[TBL] [Abstract][Full Text] [Related]
17. 7-Nitrobenzofurazan (NBD) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A(3) adenosine receptors.
Macchia M; Salvetti F; Bertini S; Di Bussolo V; Gattuso L; Gesi M; Hamdan M; Klotz KN; Laragione T; Lucacchini A; Minutolo F; Nencetti S; Papi C; Tuscano D; Martini C
Bioorg Med Chem Lett; 2001 Dec; 11(23):3023-6. PubMed ID: 11714602
[TBL] [Abstract][Full Text] [Related]
18. Direct visualisation of internalization of the adenosine A3 receptor and localization with arrestin3 using a fluorescent agonist.
Stoddart LA; Vernall AJ; Briddon SJ; Kellam B; Hill SJ
Neuropharmacology; 2015 Nov; 98():68-77. PubMed ID: 25937210
[TBL] [Abstract][Full Text] [Related]
19. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists.
Maemoto T; Finlayson K; Olverman HJ; Akahane A; Horton RW; Butcher SP
Br J Pharmacol; 1997 Nov; 122(6):1202-8. PubMed ID: 9401787
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent probes for adenosine receptors: synthesis and biology of N6-dansylaminoalkyl-substituted NECA derivatives.
Macchia M; Salvetti F; Barontini S; Calvani F; Gesi M; Hamdan M; Lucacchini A; Pellegrini A; Soldani P; Martini C
Bioorg Med Chem Lett; 1998 Nov; 8(22):3223-8. PubMed ID: 9873707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
